Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Cotadutide Formulations in Healthy Adults
NCT03341013Phase 1Completed
- Sponsor
- MedImmune
- Start
- Nov 2017
- Primary completion
- Jan 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cotadutide in type 2 diabetes mellitus (T2DM) and obesity (2 arms), sponsored by MedImmune. Primary endpoints: Area under the drug concentration curve at 48 hours and Maximum observed plasma concentration at 48 hours. Started Nov 2017; status: completed.
02
Drugs
cotadutide
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT03341013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03341013.